New triple therapy shows promise for tough lymphoma cases
Disease control
Ongoing
This early-phase study tests a combination of three drugs (obinutuzumab, venetoclax, and lenalidomide) in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work togeth…
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Jun 17, 2026 12:10 UTC